Summit Therapeutics Sinks on FDA Rejection
Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.
How this was made

The 30-second read
Why it matters
The FDA’s stance that progression-free survival alone does not establish a positive benefit-risk profile, absent statistically significant overall survival improvement, is a direct regulatory overhang for the specific indication and may force protocol, endpoint, or evidence strategy changes.
Market read
This is a direct, tradable regulatory catalyst for SMMT, with immediate price impact and clear implications for future financing and development timelines.
What to watch
No resubmission timetable is provided, but the article also notes AstraZeneca’s roughly $2bn equity investment, which could signal longer-term strategic support despite the rejection.
Background
Summit’s lung cancer drug ivonescimab is licensed from Akeso; the FDA rejection came via a complete response letter tied to overall survival evidence for the HARMONi trial program.
Ticker impact
Summit Therapeutics shares fell about 16.5% after the FDA issued a complete response letter rejecting ivonescimab plus platinum for post-EGFR lung cancer.
Likely continued downside pressure as traders price in delay risk, potential resubmission uncertainty, and dilution from future financing.
The article reports a first-session trading reaction to an FDA rejection, with no resubmission timetable and explicit dilution risk from an ATM program plus AstraZeneca equity investment.
Market effects
Reinforces stricter FDA scrutiny on overall survival endpoints versus progression-free survival in oncology trials, potentially affecting sentiment across lung cancer immuno-oncology/targeted antibody developers.
Limited direct regional spillover, but could weigh on US-listed small/mid-cap biotech risk appetite.
Akeso’s licensed asset setback may influence global biotech licensing and development expectations for similar trial designs, though the immediate catalyst is US regulatory.
Counterpoint
Summit cites a post-hoc overall survival hazard ratio favoring ivonescimab and points to other Phase III studies, suggesting the program may still be salvageable with additional evidence.
Key entities
- companySummit Therapeutics
US-listed cancer drug developer whose ivonescimab application was rejected by the FDA via a complete response letter.
- companyAkeso
Hong Kong-listed biotech that invented ivonescimab and licenses it to Summit.
- regulatorFDA
US drug regulator issuing the complete response letter for the ivonescimab plus platinum indication.
- companyAstraZeneca
Invested roughly $2bn in Summit’s financing, potentially affecting funding expectations and dilution risk.




